Cholesterol Goal Attainment in Patients with Coronary Heart Disease and Elevated Coronary Risk- Results of the Hong Kong Hospital Audit Study

Mar 1, 2008, 00:00
10.1111/j.1524-4733.2008.00372.x
https://www.valueinhealthjournal.com/article/S1098-3015(10)60652-3/fulltext
Title : Cholesterol Goal Attainment in Patients with Coronary Heart Disease and Elevated Coronary Risk- Results of the Hong Kong Hospital Audit Study
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)60652-3&doi=10.1111/j.1524-4733.2008.00372.x
First page :
Section Title :
Open access? : No
Section Order : 18

Objective

We sought to determine 1) long-term lipid-lowering treatment patterns; 2) cholesterol goal attainment rates and possible determinants of goal achievement; and 3) effects of cholesterol goal attainment on coronary events in hospitalized Hong Kong patients.

Methods

In this retrospective cohort analysis, records of two public Hong Kong hospitals were reviewed for 196 adults (69% with coronary heart disease (CHD) or CHD-risk equivalent) who received at least one lipid-lowering therapy during hospitalization. Low-density lipoprotein cholesterol (LDL-C) targets were 130 mg/dL) for those without.

Results

Most participants were initiated on regimens of low to midequipotency doses and never had their regimens adjusted to higher potency. Approximately 44% of patients not at LDL-C at baseline failed to achieve goal during a median follow-up of 1.9 years. Patients with higher coronary risk and/or LDL-C levels at baseline were less likely than their lower-risk counterparts to achieve goal; for each 1-mmol/l (38.7-mg/dL) increase in LDL-C at baseline, the likelihood of attaining goal declined by 64%. Patients achieving cholesterol goal had significantly longer cardiovascular event-free times.

Conclusions

A total of 44% of Hong Kong patients not at LDL-C goals at baseline did not achieve them over 1.9 years. More effective and well-tolerated therapies, including adjunctive regimens (e.g., ezetimibe-statin, niacin-statin), may be necessary to enhance LDL-C goal achievement and increase event-free time.

Categories :
  • Cardiovascular Disorders
  • Clinical Outcomes
  • Clinician Reported Outcomes
  • Retrospective Databases: Electronic Medical and Health Records, Admin Claims
  • Specific Diseases & Conditions
  • Study Approaches
Tags :
  • coronary disease
  • hydroxymethylglutaryl CoA reductase inhibitors
  • hypercholesterolemia
  • prevention and control
Regions :
  • Asia Pacific (including Oceania)
ViH Article Tags :